Alemtuzumab and intrathecal methotrexate failed in the therapy of Rasmussen encephalitis
Authors:
- Zuzana LibaZLZuzana Liba
- Petr SedlacekPSPetr Sedlacek
- Vera SebronovaVSVera Sebronova
- Alice MaulisovaAMAlice Maulisova
- Bertil RydenhagBRBertil Rydenhag
- Josef ZamecnikJZJosef Zamecnik
- Martin KynclMKMartin Kyncl
- Pavel KrsekPKPavel Krsek
Open Access
- 1 July 2017
- journal article
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 4 (4) , e354
Abstract
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.Keywords
This publication has 8 references indexed in Scilit:
- ALAIN01—Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potentialBMC Neurology, 2016
- Rasmussen encephalitis: Response to early immunotherapy in a case of immune-mediated encephalitisNeurology Neuroimmunology & Neuroinflammation, 2015
- Rasmussen's encephalitis: clinical features, pathobiology, and treatment advancesThe Lancet Neurology, 2014
- Clinical application and evaluation of the Bien diagnostic criteria for Rasmussen encephalitisEpilepsia, 2013
- Prevalence and treatment of anti-NMDA receptor encephalitisThe Lancet Neurology, 2013
- Prevalence and treatment of anti-NMDA receptor encephalitisThe Lancet Neurology, 2013
- Treatment of Rasmussen encephalitis half a century after its initial description: Promising prospects and a dilemmaEpilepsy Research, 2009
- A case of Rasmussen encephalitis treated with rituximabNature Reviews Neurology, 2009